Description: Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd., together with its subsidiaries, researches, develops, manufactures, and sells bio-pharmaceutical products. It offers genetic engineering platform drugs, including CD30-DM1 antibody-drug conjugate (ADC), which is in Phase I clinical trials for tumors; Trop2-SN38 ADC that is in Phase I clinical trials for triple negative, breast, bladder, gastric, and other tumors; Trop2-BB05 ADC that is in pre-clinical studies for lung cancer and triple negative breast cancer; and HER2 ADC that has completed pre-clinical research for metastatic breast and gastric cancers. The company also provides photodynamic technical platform drugs, such as hemoporfin for port wine stain, which is in Phase IV clinical trial; and aminolevulinic acid, which is in Phase II clinical trials for cervical diseases infected by HPV and acne, as well as completed pre-clinical study for brain gliomas. In addition, it offers nano technical platform drugs, such as Nanoparticle Albumin-bound Paclitaxel that is in pre-clinical studies for tumors, as well as developing Doxorubicin liposome for tumors. Further, the company offers oral solid preparation technology, which includes obeticholic acid for hepatobiliary and autoimmune disease; timolol maleate cream that is in pre-clinical studies for infantile hemangioma; and FZJ-003 oral preparation, which is in Phase I clinical trials for rheumatoid arthritis, as well as in Phase II clinical trials for atopic dermatitis and ulcerative colitis. Additionally, it develops pharmaceutical and medical devices; medical diagnostic products and related services; and sells daily necessities, and clinical laboratory analysis instruments and software. It also engages in the technology development, transfer, consulting, and promotion activities; produces freeze-dried powder injections and APIs; and invests in overseas medical projects. The company was founded in 1996 and is based in Shanghai, the People's Republic of China.
Home Page: www.fd-zj.com
Zhangjiang Hi-Tech Park
Shanghai,
201210
China
Phone:
86 21 5895 3355
Officers
| Name | Title |
|---|---|
| Mr. Hai Bo Wang | Co-Founder, Chairman & GM |
| Mr. Da Jun Zhao | Co-Founder, Deputy GM & Exec. Director |
| Mr. Yong Su | Deputy GM & Exec. Director |
| Mr. Jun Li | Co-Founder & Deputy GM |
| Ms. Xue Yan FCCA, HKICPA, ACCA, CICPA, CIA | CFO & Company Sec. |
| Mr. Xiaolin Yang | Deputy Gen. Mang. |
| Mr. Yi Min Gan | Deputy Gen. Mang. |
| Ms. Dai Qing Yu | Quality Director & Employee Representative Supervisor |
Exchange: HK
Country: HK
Currency: Hong Kong Dollar (HK$)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Pharmaceuticals |
| GIC Sub-Industry: | Pharmaceuticals |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 28.6667 |
| Price-to-Book MRQ: | 1.2995 |
| Price-to-Sales TTM: | 7.3756 |
| IPO Date: | 2002-08-13 |
| Fiscal Year End: | December |
| Full Time Employees: | 776 |